AU2018243554C1 - Generation of therapeutic cells using extracellular components of target organs - Google Patents

Generation of therapeutic cells using extracellular components of target organs Download PDF

Info

Publication number
AU2018243554C1
AU2018243554C1 AU2018243554A AU2018243554A AU2018243554C1 AU 2018243554 C1 AU2018243554 C1 AU 2018243554C1 AU 2018243554 A AU2018243554 A AU 2018243554A AU 2018243554 A AU2018243554 A AU 2018243554A AU 2018243554 C1 AU2018243554 C1 AU 2018243554C1
Authority
AU
Australia
Prior art keywords
cells
macrophages
tissue
specific
educated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018243554A
Other languages
English (en)
Other versions
AU2018243554B2 (en
AU2018243554A1 (en
Inventor
Peiman Hematti
John A. Kink
Amish N. Raval
Eric G. Schmuck
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wisconsin Alumni Research Foundation
Original Assignee
Wisconsin Alumni Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wisconsin Alumni Research Foundation filed Critical Wisconsin Alumni Research Foundation
Publication of AU2018243554A1 publication Critical patent/AU2018243554A1/en
Publication of AU2018243554B2 publication Critical patent/AU2018243554B2/en
Application granted granted Critical
Publication of AU2018243554C1 publication Critical patent/AU2018243554C1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0645—Macrophages, e.g. Kuepfer cells in the liver; Monocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/33—Fibroblasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/17—Monocytes; Macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/418—Antigens related to induction of tolerance to non-self
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/70—Undefined extracts
    • C12N2500/80—Undefined extracts from animals
    • C12N2500/84—Undefined extracts from animals from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
    • C12N2502/1323—Adult fibroblasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
    • C12N2502/1352—Mesenchymal stem cells
    • C12N2502/1358—Bone marrow mesenchymal stem cells (BM-MSC)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Microbiology (AREA)
  • Vascular Medicine (AREA)
  • Biochemistry (AREA)
  • Botany (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
AU2018243554A 2017-03-31 2018-03-30 Generation of therapeutic cells using extracellular components of target organs Active AU2018243554C1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
NL2018628 2017-03-31
NL2018628 2017-03-31
PCT/US2018/025371 WO2018183825A1 (en) 2017-03-31 2018-03-30 Generation of therapeutic cells using extracellular components of target organs

Publications (3)

Publication Number Publication Date
AU2018243554A1 AU2018243554A1 (en) 2019-10-17
AU2018243554B2 AU2018243554B2 (en) 2024-02-15
AU2018243554C1 true AU2018243554C1 (en) 2025-01-30

Family

ID=58548819

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018243554A Active AU2018243554C1 (en) 2017-03-31 2018-03-30 Generation of therapeutic cells using extracellular components of target organs

Country Status (7)

Country Link
US (2) US11760975B2 (https=)
EP (1) EP3600354B1 (https=)
JP (2) JP7249951B2 (https=)
AU (1) AU2018243554C1 (https=)
CA (1) CA3058437A1 (https=)
DK (1) DK3600354T3 (https=)
WO (1) WO2018183825A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2949083C (en) 2014-05-18 2023-10-10 Children's Medical Center Corporation Methods and compositions relating to exosomes
US11738046B2 (en) 2017-11-03 2023-08-29 Wisconsin Alumni Research Foundation Macrophage cell therapy to treat orthopedic injury
US10876753B2 (en) 2018-02-12 2020-12-29 Watsco Ventures Llc Integrated sensor and service port for HVAC equipment or HVAC system
CN112334190B (zh) 2018-04-30 2024-09-20 儿童医学中心公司 间充质基质细胞外排体及其用途
CA3099042A1 (en) * 2018-05-09 2019-11-14 Children's Medical Center Corporation Mesenchymal stromal cell exosome -treated monocytes and uses thereof
US12350293B2 (en) 2019-03-08 2025-07-08 Niigata University Induction method for macrophage, anti-inflammatory macrophage-inducing agent, and pharmaceutical composition
US20230071393A1 (en) * 2020-04-16 2023-03-09 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Matrix bound vesicles (mbv) for treatment of acute respiratory distress syndrome
EP3984527A1 (en) 2020-10-13 2022-04-20 Ludwig-Maximilians-Universität München Nano-in-micro encapsulated sirna dry powder, method for producing the same and use of a powder formulation as a pharmaceutical dosage form, in particular for pulmonary delivery
US20220127579A1 (en) * 2020-10-22 2022-04-28 Wisconsin Alumni Research Foundation Use of Toll-Like Receptor 4 Agonists to Treat Inflammation and Tissue Injury
WO2023003775A2 (en) * 2021-07-21 2023-01-26 The Regents Of The University Of California Human ipsc-derived macrophages for liver repair and regeneration
EP4398948A4 (en) * 2021-09-07 2025-07-09 Wisconsin Alumni Res Found CARDIAC FIBROBLAST-DERIVED EXTRACELLULAR MATRIX

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110045071A1 (en) * 2009-08-24 2011-02-24 Peiman Hematti Generation of a novel type of anti-inflammatory macrophages for clinical use
US20120183575A1 (en) * 2009-07-02 2012-07-19 Ith Immune Therapy Holdings Ab Exosome based treatment of cancer
WO2015031376A1 (en) * 2013-08-26 2015-03-05 The Trustees Of Columbia University In The City Of New York Scaffolds containing cytokines for tissue engineering

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8802144B2 (en) 2011-08-25 2014-08-12 Wisconsin Alumni Research Foundation 3-dimensional cardiac fibroblast derived extracellular matrix
US10624930B2 (en) 2014-06-10 2020-04-21 Mesoblast International Sarl Treatment of immune disorders
US10166254B2 (en) 2014-09-19 2019-01-01 Wisconsin Alumni Research Foundation Use of mesenchymal stem cell-educated macrophages to treat and prevent graft versus host disease and radiation-induced injury
EP3204117A4 (en) * 2014-10-06 2018-05-09 Cedars-Sinai Medical Center Polarization of macrophages to a healing phenotype by cardiosphere-derived cells and by the exosomes secreted by such cells
KR20180015187A (ko) 2015-06-03 2018-02-12 위스콘신 얼럼나이 리서어치 화운데이션 심장 섬유모세포-유래된 세포외 기질 및 허혈성 질환 또는 손상의 치료를 위한 이의 주사 가능한 제형
US11738046B2 (en) 2017-11-03 2023-08-29 Wisconsin Alumni Research Foundation Macrophage cell therapy to treat orthopedic injury

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120183575A1 (en) * 2009-07-02 2012-07-19 Ith Immune Therapy Holdings Ab Exosome based treatment of cancer
US20110045071A1 (en) * 2009-08-24 2011-02-24 Peiman Hematti Generation of a novel type of anti-inflammatory macrophages for clinical use
WO2015031376A1 (en) * 2013-08-26 2015-03-05 The Trustees Of Columbia University In The City Of New York Scaffolds containing cytokines for tissue engineering

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
HUMERES CLAUDIO ET AL: JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, ACADEMIC PRESS, GB, vol. 101, 27 October 2016 (2016-10-27), pages 69 - 80, XP029833355, ISSN: 0022-2828, DOI: 10.1016/J.YJMCC.2016.10.014 *
KIM J; HEMATTI P: "Mesenchymal stem cell-educated macrophages: A novel type of alternatively activated macrophages", EXPERIMENTAL HEMATOLOGY, vol. 37, 2009, pages 1445 - 1453, XP026756830, DOI: doi:10.1016/j.exphem.2009.09.004 *
MANABU SHIRAISHI ET AL: JOURNAL OF CLINICAL INVESTIGATION, vol. 126, no. 6, 1 June 2016 (2016-06-01), US, pages 2151 - 2166, XP055369099, ISSN: 0021-9738, DOI: 10.1172/JCI85782 *
Wei et al., Frontiers in Pharmacology 2021, 11:590470 (Year: 2021) *

Also Published As

Publication number Publication date
WO2018183825A1 (en) 2018-10-04
DK3600354T3 (da) 2023-10-30
US20230407256A1 (en) 2023-12-21
EP3600354A1 (en) 2020-02-05
JP2023052043A (ja) 2023-04-11
AU2018243554B2 (en) 2024-02-15
JP2020511999A (ja) 2020-04-23
AU2018243554A1 (en) 2019-10-17
CA3058437A1 (en) 2018-10-04
US11760975B2 (en) 2023-09-19
JP7249951B2 (ja) 2023-03-31
EP3600354B1 (en) 2023-09-20
US20180282698A1 (en) 2018-10-04
JP7419490B2 (ja) 2024-01-22

Similar Documents

Publication Publication Date Title
US20230407256A1 (en) Generation of therapeutic cells using extracellular components of target organs
EP2874634B1 (en) Use of preparations comprising exosomes derived from mesenchymal stem cells (mscs) in the prevention and therapy of inflammatory conditions
Kim et al. Amniotic mesenchymal stem cells have robust angiogenic properties and are effective in treating hindlimb ischaemia
CN108671224B (zh) 血小板裂解物的组合物、用途和制备
US20190353643A1 (en) Method For Sorting Highly Effective Stem Cells For Treating Immune Disorder
ES2914692T3 (es) Células madre adhesivas derivadas de cordón umbilical mejoradas, método de preparación para las mismas, y uso de las mismas
JP6472390B2 (ja) 成体心臓幹細胞集団
US20240191201A1 (en) Extracellular vesicles from mesenchymal stromal cells for treatment of diseases
JP5894071B2 (ja) 心臓組織由来細胞
JP2020533392A (ja) 血管障害を治療するための調節性マクロファージ
JP2022551103A (ja) 骨髄間葉系幹細胞由来細胞集団およびその調製方法
Leal et al. Immune effects of mesenchymal stem cells: Implications for Charcot–Marie–Tooth disease
CN120418416A (zh) 用于使间充质干细胞向脂肪细胞的分化能力增强的组合物
CN120035655A (zh) 新的牙髓干细胞群
KR20230128452A (ko) 중간엽 줄기 세포 및 이의 배양
Antunes Developing an Advanced Therapy Medicinal Product (ATMP) for the treatment of GvHD

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 18 SEP 2024

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT FILED 18 SEP 2024